Lyell Immunopharma (LYEL) Net Cash Flow (2020 - 2026)

Lyell Immunopharma's Net Cash Flow history runs 7 years deep, the most recent figure standing at $30.6 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 107.69% year-over-year to $30.6 million; the TTM figure through Mar 2026 stood at -$29.7 million (down 656.63% YoY), while the FY2025 annual figure was -$45.5 million, down 17.8% from the prior year.
• Net Cash Flow came in at $30.6 million for Q1 2026 at Lyell Immunopharma, up from -$63.4 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $114.9 million in Q2 2023 to a low of -$140.6 million in Q4 2023.
• A 5-year average of -$11.9 million and a median of -$14.1 million in 2023 frame the typical range for Net Cash Flow.
• On a YoY basis, Net Cash Flow climbed as much as 781.89% in 2023 and fell as far as 2040.45% in 2023.
• Lyell Immunopharma's Net Cash Flow stood at $7.2 million in 2022, then tumbled by 2040.45% to -$140.6 million in 2023, then soared by 104.77% to $6.7 million in 2024, then tumbled by 1046.18% to -$63.4 million in 2025, then surged by 148.25% to $30.6 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $30.6 million, -$63.4 million, and $24.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison